Uncover What Real-World Data Means for Moderate-To-Severe Psoriasis Patients

This episode is intended for patients with moderate-to-severe plaque psoriasis and health care providers who treat this condition.

Treatment options backed by real-world evidence mean more opportunities for those living with moderate-to-severe plaque psoriasis. Join Steve Rozzo, Ph.D., Associate Vice President and Head, Biologics Medical Affairs, Sun Pharma, North America, and Neal Bhatia, M.D., Therapeutics Clinical Research in San Diego, CA, in a Q&A discussion on real-world clinical data of ILUMYA® and what the findings mean for moderate-to-severe plaque psoriasis patients and health care providers.